WEKO3
AND
アイテム
{"_buckets": {"deposit": "74b7d266-5234-465e-b7e1-3b783007f6d1"}, "_deposit": {"id": "22677", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "22677"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00022677"}, "item_7_alternative_title_1": {"attribute_name": "\u305d\u306e\u4ed6\u306e\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_alternative_title": "The Thrapeutic Model of Systemic Lupus Erythematosus(Autoimmune Diseases)"}]}, "item_7_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "1989-12", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "12", "bibliographicPageEnd": "982", "bibliographicPageStart": "977", "bibliographicVolumeNumber": "103", "bibliographic_titles": [{"bibliographic_title": "\u65b0\u6f5f\u533b\u5b66\u4f1a\u96d1\u8a8c"}, {"bibliographic_title": "\u65b0\u6f5f\u533b\u5b66\u4f1a\u96d1\u8a8c", "bibliographic_titleLang": "en"}]}]}, "item_7_description_4": {"attribute_name": "\u6284\u9332", "attribute_value_mlt": [{"subitem_description": "The therapeutic effect of 15\uff0ddeoxyspergualin (DSP), a newly developed immunosuppressive agent, on the development of spontaneously occuring lupus glomerulonephritis in MRL/1pr and male BXSB mice was examined. Administration of the drug was begun from the age of 13 weeks, when polyclonal B cell activation and lupus nephropathy were apparent. Treatment with DSP up to 20 weeks of age at a dose of 2mg/kg twice a day, 5mg/kg daily or 20mg/kg three times a week strongly suppressed the increment of IgG-producing cell numbers in the spleen, and decreased serum levels of immune complexes and anti-DNA antibodies. Glomerular histological score by light microscopy and IgG and C3 deposition estimated by immunofluorescence were remarkably improved. In MRL/1pr mice, DSP reduced the swelling of lymph node and the numbers of Thy-1^+, B220^+ cell population in lymphoid organs. Responsiveness to Con A and IL-2 production of spleen cells were improved by the treatment. Thus, DSP was shown to suppress the progression of polyclonal B cell activation and lupus nephropathy in MRL/1pr and male BXSB mice. These results suggest that DSP might be used as a therapeutic agent for human erythematosus.", "subitem_description_type": "Abstract"}]}, "item_7_full_name_3": {"attribute_name": "\u8457\u8005\u5225\u540d", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "137505", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Ito, Satoshi"}]}, {"nameIdentifiers": [{"nameIdentifier": "137506", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Fujiwara, Michio"}]}, {"nameIdentifiers": [{"nameIdentifier": "137507", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Arakawa, Masaaki"}]}]}, "item_7_publisher_7": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "\u65b0\u6f5f\u533b\u5b66\u4f1a"}]}, "item_7_select_19": {"attribute_name": "\u8457\u8005\u7248\u30d5\u30e9\u30b0", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_7_source_id_11": {"attribute_name": "\u66f8\u8a8c\u30ec\u30b3\u30fc\u30c9ID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00182415", "subitem_source_identifier_type": "NCID"}]}, "item_7_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00290440", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "\u4f0a\u85e4, \u8061"}], "nameIdentifiers": [{"nameIdentifier": "137502", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "\u85e4\u539f, \u9053\u592b"}], "nameIdentifiers": [{"nameIdentifier": "137503", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "\u8352\u5ddd, \u6b63\u662d"}], "nameIdentifiers": [{"nameIdentifier": "137504", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-08-19"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "103(12)_977-982.pdf", "filesize": [{"value": "2.6 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 2600000.0, "url": {"label": "103(12)_977-982.pdf", "url": "https://niigata-u.repo.nii.ac.jp/record/22677/files/103(12)_977-982.pdf"}, "version_id": "b161f1f5-bd68-4704-b151-f927e1dbdf83"}]}, "item_keyword": {"attribute_name": "\u30ad\u30fc\u30ef\u30fc\u30c9", "attribute_value_mlt": [{"subitem_subject": "Murine Lupus", "subitem_subject_scheme": "Other"}, {"subitem_subject": "MRL/1pr mice", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Male BXSB mice", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Polyclonal B cell activation", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Immunosuppressant", "subitem_subject_scheme": "Other"}, {"subitem_subject": "\u30eb\u30fc\u30d7\u30b9\u30e2\u30c7\u30eb\u30de\u30a6\u30b9", "subitem_subject_scheme": "Other"}, {"subitem_subject": "MRL/1pr\u30de\u30a6\u30b9", "subitem_subject_scheme": "Other"}, {"subitem_subject": "BXSB\u96c4\u30de\u30a6\u30b9", "subitem_subject_scheme": "Other"}, {"subitem_subject": "\u591a\u30af\u30ed\u30fc\u30f3\u6027B\u7d30\u80de\u6d3b\u6027\u5316", "subitem_subject_scheme": "Other"}, {"subitem_subject": "\u514d\u75ab\u6291\u5236\u5264", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "4) \u30a8\u30ea\u30c6\u30de\u30c8\u30fc\u30c7\u30b9\u306e\u6cbb\u7642\u30e2\u30c7\u30eb(\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0 \u81ea\u5df1\u514d\u75ab\u75be\u60a3, \u7b2c445\u56de\u65b0\u6f5f\u533b\u5b66\u4f1a)", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "4) \u30a8\u30ea\u30c6\u30de\u30c8\u30fc\u30c7\u30b9\u306e\u6cbb\u7642\u30e2\u30c7\u30eb(\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0 \u81ea\u5df1\u514d\u75ab\u75be\u60a3, \u7b2c445\u56de\u65b0\u6f5f\u533b\u5b66\u4f1a)"}, {"subitem_title": "4) \u30a8\u30ea\u30c6\u30de\u30c8\u30fc\u30c7\u30b9\u306e\u6cbb\u7642\u30e2\u30c7\u30eb(\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0 \u81ea\u5df1\u514d\u75ab\u75be\u60a3, \u7b2c445\u56de\u65b0\u6f5f\u533b\u5b66\u4f1a)", "subitem_title_language": "en"}]}, "item_type_id": "7", "owner": "1", "path": ["453/456", "471/537/538/1203"], "permalink_uri": "http://hdl.handle.net/10191/41469", "pubdate": {"attribute_name": "\u516c\u958b\u65e5", "attribute_value": "2016-04-13"}, "publish_date": "2016-04-13", "publish_status": "0", "recid": "22677", "relation": {}, "relation_version_is_last": true, "title": ["4) \u30a8\u30ea\u30c6\u30de\u30c8\u30fc\u30c7\u30b9\u306e\u6cbb\u7642\u30e2\u30c7\u30eb(\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0 \u81ea\u5df1\u514d\u75ab\u75be\u60a3, \u7b2c445\u56de\u65b0\u6f5f\u533b\u5b66\u4f1a)"], "weko_shared_id": null}
4) エリテマトーデスの治療モデル(シンポジウム 自己免疫疾患, 第445回新潟医学会)
http://hdl.handle.net/10191/41469
9d6c16ba-e00e-4619-a2a5-2efc9be93d90
名前 / ファイル | ライセンス | アクション | |
---|---|---|---|
![]() |
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2016-04-13 | |||||
タイトル | ||||||
タイトル | 4) エリテマトーデスの治療モデル(シンポジウム 自己免疫疾患, 第445回新潟医学会) | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | 4) エリテマトーデスの治療モデル(シンポジウム 自己免疫疾患, 第445回新潟医学会) | |||||
言語 | ||||||
言語 | jpn | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Murine Lupus | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | MRL/1pr mice | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Male BXSB mice | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Polyclonal B cell activation | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Immunosuppressant | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | ループスモデルマウス | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | MRL/1prマウス | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | BXSB雄マウス | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | 多クローン性B細胞活性化 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | 免疫抑制剤 | |||||
資源タイプ | ||||||
資源 | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | departmental bulletin paper | |||||
その他のタイトル | ||||||
その他のタイトル | The Thrapeutic Model of Systemic Lupus Erythematosus(Autoimmune Diseases) | |||||
著者 |
伊藤, 聡
× 伊藤, 聡× 藤原, 道夫× 荒川, 正昭 |
|||||
著者別名 | ||||||
識別子 | ||||||
識別子 | 137505 | |||||
識別子Scheme | WEKO | |||||
姓名 | ||||||
姓名 | Ito, Satoshi | |||||
著者別名 | ||||||
識別子 | ||||||
識別子 | 137506 | |||||
識別子Scheme | WEKO | |||||
姓名 | ||||||
姓名 | Fujiwara, Michio | |||||
著者別名 | ||||||
識別子 | ||||||
識別子 | 137507 | |||||
識別子Scheme | WEKO | |||||
姓名 | ||||||
姓名 | Arakawa, Masaaki | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | The therapeutic effect of 15-deoxyspergualin (DSP), a newly developed immunosuppressive agent, on the development of spontaneously occuring lupus glomerulonephritis in MRL/1pr and male BXSB mice was examined. Administration of the drug was begun from the age of 13 weeks, when polyclonal B cell activation and lupus nephropathy were apparent. Treatment with DSP up to 20 weeks of age at a dose of 2mg/kg twice a day, 5mg/kg daily or 20mg/kg three times a week strongly suppressed the increment of IgG-producing cell numbers in the spleen, and decreased serum levels of immune complexes and anti-DNA antibodies. Glomerular histological score by light microscopy and IgG and C3 deposition estimated by immunofluorescence were remarkably improved. In MRL/1pr mice, DSP reduced the swelling of lymph node and the numbers of Thy-1^+, B220^+ cell population in lymphoid organs. Responsiveness to Con A and IL-2 production of spleen cells were improved by the treatment. Thus, DSP was shown to suppress the progression of polyclonal B cell activation and lupus nephropathy in MRL/1pr and male BXSB mice. These results suggest that DSP might be used as a therapeutic agent for human erythematosus. | |||||
書誌情報 |
新潟医学会雑誌 en : 新潟医学会雑誌 巻 103, 号 12, p. 977-982, 発行日 1989-12 |
|||||
出版者 | ||||||
出版者 | 新潟医学会 | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 00290440 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AN00182415 | |||||
著者版フラグ | ||||||
値 | publisher |